Prof Dr Karin Fijnvandraat


Prof Dr Karin Fijnvandraat

Research and teaching mandate (leeropdracht) HEMOPHILIA - ETIOLOGY AND TREATMENT OF INHIBITOR DEVELOPMENT IN MILD HEMOPHILIA A Hemophilia A (Factor VIII deficiency) is a rare bleeding disorder that is treated by intravenous administration of clotting factor concentrates. A major challenge in the treatment is the development of inhibiting antibodies (inhibitors), directed towards F VIII. Inhibitors block the action of F VIII and thereby increase morbidity and mortality. My research group aims to identify clinical and genetic risk factors for inhibitor development, especially in mild/moderate hemophilia. For this purpose the INSIGHT consortium was established, including 34 hospitals in 11 countries caring for 2700 moderate and mild hemophilia A patients. Treatment of inhibitors in moderate and mild hemophilia is investigated in the TRIM study. DDAVP can be used as a treatment for bleedings circumventing the use of clotting factor concentrates, thereby reducing the risk of inhibitor development. The RISE study identifies predictors of DDAVP response in mild hemophilia A patients. SICKLE CELL DISEASE Sickle Cell Disease is a hereditary anemia caused by a mutation in the beta-globulin gene, that occurs predominantly in persons with African ancestry. Hallmarks of the disease are chronic haemolytic anemia and vascular occlusion, that may cause irreversible damage to all vital organs. Blood transfusions are frequently administered to prevent or treat complications associated with the disease. My research group is working on ways to reduce painfull crises, improve neurocognitive outcome and prevent allo-immunisation after blood transfusion.
Expertise Hematology Hemophilia Antbodies against biologicals Sickle cell disease Blood tranfusion
Email c.j.fijnvandraat@amc.nl
Organisation Universiteit van Amsterdam (UvA)

« Back to affiliates